Black Diamond Therapeutics Inc. (BDTX)
$2.12
$0.02
(0.95%)
As on 04-Sep-2026 16:00EDT
Market cap
$121 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
2.6
-
Debt to Equity
0
-
Book Value
$1.7
-
EPS
$-0.7
-
Face value
--
-
Shares outstanding
57,301,774
7 Years Aggregate
CFO
$-339.57 Mln
EBITDA
$-409.84 Mln
Net Profit
$-410.32 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Black Diamond Therapeutics (BDTX)
| -12.8 | 22.2 | 1.0 | -26.4 | -15.9 | -26.4 | -- |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Black Diamond Therapeutics (BDTX)
| 13.6 | -23.7 | 56.1 | -66.2 | -83.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Black Diamond Therapeutics (BDTX)
|
2.1 | 121.5 | 0.0 | -42.6 | -- | -40.9 | -- | 1.4 |
| 86.3 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 72.7 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 59.0 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 110.2 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 358.2 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 117.4 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 541.1 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 591.3 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 |
Shareholding Pattern
View DetailsAbout Black Diamond Therapeutics (BDTX)
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant... epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Read more
-
CEO, President & Chairman
Dr. Mark A. Velleca M.D., Ph.D.
-
CEO, President & Chairman
Dr. Mark A. Velleca M.D., Ph.D.
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Black Diamond Therapeutics (BDTX)
What is the current share price of Black Diamond Therapeutics Inc (BDTX) Today?
The share price of Black Diamond Therapeutics Inc (BDTX) is $2.12 (NASDAQ) as of 04-Sep-2026 16:00 EDT. Black Diamond Therapeutics Inc (BDTX) has given a return of -15.87% in the last 3 years.
What is the current PB & PE ratio of Black Diamond Therapeutics Inc (BDTX)?
Since, TTM earnings of Black Diamond Therapeutics Inc (BDTX) is negative, P/E ratio is not available.
The P/B ratio of Black Diamond Therapeutics Inc (BDTX) is 1.36 times as on 04-Sep-2026, a 74 discount to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
6.20 |
1.24 |
2024 |
-1.74 |
1.45 |
2023 |
-1.62 |
1.14 |
2022 |
-0.72 |
0.57 |
2021 |
-1.54 |
0.99 |
What is the 52 Week High and Low of Black Diamond Therapeutics Inc (BDTX)?
The 52-week high and low of Black Diamond Therapeutics Inc (BDTX) are Rs 4.94 and Rs 1.60 as of 07-Sep-2026.
What is the market cap of Black Diamond Therapeutics Inc (BDTX)?
Black Diamond Therapeutics Inc (BDTX) has a market capitalisation of $ 121 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Black Diamond Therapeutics Inc (BDTX)?
Before investing in Black Diamond Therapeutics Inc (BDTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.